2,4-thiazolidinedione has been researched along with Innate Inflammatory Response in 15 studies
thiazolidine-2,4-dione: structure in first source
1,3-thiazolidine-2,4-dione : A thiazolidenedione carrying oxo substituents at positions 2 and 4.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In impaired glucose tolerance subjects, these procedures were performed before and after treatment with pioglitazone or metformin." | 3.74 | Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation. ( Bodles, AM; Fried, SK; Kern, LM; Kern, PA; Lee, MJ; McGehee, RE; Phanavanh, B; Rasouli, N; Spencer, HJ; Starks, T; Varma, V; Yao-Borengasser, A, 2007) |
| "A total of 2368 patients with type 2 diabetes mellitus and clinically stable, angiographically documented coronary artery disease were randomized to treatment with 1 of the 2 strategies and followed for an average of 5 years." | 2.76 | Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. ( Brooks, MM; Frye, RL; Genuth, S; Hardison, RM; Huber, K; Krishnaswami, A; McBane, RD; Pratley, RE; Schneider, DJ; Sobel, BE; Wolk, R, 2011) |
| "Type 2 diabetes is the most common cause of chronic renal failure worldwide." | 2.44 | Antiproteinuric and anti-inflammatory effects of thiazolidinedione. ( Li, PK; Szeto, CC, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (80.00) | 29.6817 |
| 2010's | 3 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Takei, Y | 1 |
| Tontonoz, P | 1 |
| Spiegelman, BM | 1 |
| Ma, L | 1 |
| Xie, C | 1 |
| Ma, Y | 1 |
| Liu, J | 1 |
| Xiang, M | 1 |
| Ye, X | 1 |
| Zheng, H | 1 |
| Chen, Z | 1 |
| Xu, Q | 1 |
| Chen, T | 1 |
| Chen, J | 1 |
| Yang, J | 1 |
| Qiu, N | 1 |
| Wang, G | 1 |
| Liang, X | 1 |
| Peng, A | 1 |
| Yang, S | 1 |
| Wei, Y | 1 |
| Chen, L | 1 |
| Sobel, BE | 1 |
| Hardison, RM | 1 |
| Genuth, S | 1 |
| Brooks, MM | 1 |
| McBane, RD | 1 |
| Schneider, DJ | 1 |
| Pratley, RE | 1 |
| Huber, K | 1 |
| Wolk, R | 1 |
| Krishnaswami, A | 1 |
| Frye, RL | 1 |
| Pathak, R | 1 |
| Afaq, A | 1 |
| Blonde, L | 1 |
| Tugwood, JD | 1 |
| Montague, CT | 1 |
| Takahashi, N | 1 |
| Kawada, T | 1 |
| Goto, T | 1 |
| Kim, CS | 1 |
| Taimatsu, A | 1 |
| Egawa, K | 1 |
| Yamamoto, T | 1 |
| Jisaka, M | 1 |
| Nishimura, K | 1 |
| Yokota, K | 1 |
| Yu, R | 1 |
| Fushiki, T | 1 |
| Ziegler, D | 1 |
| Sung, B | 1 |
| Park, S | 1 |
| Yu, BP | 1 |
| Chung, HY | 1 |
| Hartge, MM | 1 |
| Kintscher, U | 1 |
| Unger, T | 1 |
| Varma, V | 1 |
| Yao-Borengasser, A | 1 |
| Rasouli, N | 1 |
| Bodles, AM | 1 |
| Phanavanh, B | 1 |
| Lee, MJ | 1 |
| Starks, T | 1 |
| Kern, LM | 1 |
| Spencer, HJ | 1 |
| McGehee, RE | 1 |
| Fried, SK | 1 |
| Kern, PA | 1 |
| Szeto, CC | 1 |
| Li, PK | 1 |
| Tomita, K | 1 |
| Hanafusa, T | 1 |
| Murphy, GJ | 1 |
| Holder, JC | 1 |
| Fajas, L | 1 |
| Debril, MB | 1 |
| Auwerx, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes[NCT00006305] | Phase 3 | 2,368 participants (Actual) | Interventional | 2000-09-30 | Completed | ||
| Effects of Insulin Sensitizers in Subjects With Impaired Glucose Tolerance[NCT00108615] | Phase 4 | 48 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00006305)
Timeframe: five years
| Intervention | participants (Number) |
|---|---|
| Revascularization and Insulin Providing (IP) | 80 |
| Revascularization and Insulin Sensitizing (IS) | 75 |
| Medical Therapy and Insulin Providing (IP) | 80 |
| Medical Therapy and Insulin Sensitizing (IS) | 81 |
(NCT00006305)
Timeframe: five years
| Intervention | participants (Number) |
|---|---|
| Revascularization and Insulin Providing (IP) | 145 |
| Revascularization and Insulin Sensitizing (IS) | 121 |
| Medical Therapy and Insulin Providing (IP) | 143 |
| Medical Therapy and Insulin Sensitizing (IS) | 140 |
10 reviews available for 2,4-thiazolidinedione and Innate Inflammatory Response
| Article | Year |
|---|---|
Treatment of non-alcoholic fatty liver disease.
Topics: Animals; Fatty Liver; Humans; Inflammation; Insulin Resistance; Life Style; Liver Transplantation; M | 2013 |
Fat and beyond: the diverse biology of PPARgamma.
Topics: Adipocytes; Adipogenesis; Animals; Cell Nucleus; Humans; Inflammation; Insulin Resistance; Macrophag | 2008 |
Thiazolidinediones in the treatment of managed care patients with type 2 diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hyperlipidemias; H | 2002 |
Biology and toxicology of PPARgamma ligands.
Topics: Diabetes Mellitus, Type 2; DNA-Binding Proteins; Humans; Hyperlipidemias; Hypoglycemic Agents; Infla | 2002 |
Type 2 diabetes as an inflammatory cardiovascular disorder.
Topics: Adiponectin; Animals; Anti-Inflammatory Agents; Arteriosclerosis; Cardiovascular Diseases; Diabetes | 2005 |
Endothelial dysfunction and its role in diabetic vascular disease.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelium, Vascular; Hu | 2006 |
Antiproteinuric and anti-inflammatory effects of thiazolidinedione.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; In | 2008 |
[PPARs, cancer cells and inflammation].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Differentiation; Cytokines; Humans; Inflammat | 2000 |
PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer.
Topics: Animals; Diabetes Mellitus, Type 2; DNA-Binding Proteins; Humans; Inflammation; Ligands; Neoplasms; | 2000 |
PPAR gamma: an essential role in metabolic control.
Topics: Adipose Tissue; Animals; Arteriosclerosis; Gene Expression; Humans; Inflammation; Insulin; Ligands; | 2001 |
1 trial available for 2,4-thiazolidinedione and Innate Inflammatory Response
| Article | Year |
|---|---|
Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.
Topics: Adult; Biomarkers; C-Reactive Protein; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Co | 2011 |
4 other studies available for 2,4-thiazolidinedione and Innate Inflammatory Response
| Article | Year |
|---|---|
Synthesis and biological evaluation of novel 5-benzylidenethiazolidine-2,4-dione derivatives for the treatment of inflammatory diseases.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Benzylidene Compounds; Carrageenan; Cell | 2011 |
Abietic acid activates peroxisome proliferator-activated receptor-gamma (PPARgamma) in RAW264.7 macrophages and 3T3-L1 adipocytes to regulate gene expression involved in inflammation and lipid metabolism.
Topics: 3T3 Cells; Abietanes; Adipocytes; Animals; CD36 Antigens; Cells, Cultured; CREB-Binding Protein; Cyc | 2003 |
Amelioration of age-related inflammation and oxidative stress by PPARgamma activator: suppression of NF-kappaB by 2,4-thiazolidinedione.
Topics: Aging; Animals; Cyclooxygenase 2; Gene Expression Regulation; Inflammation; Kidney; Male; NF-kappa B | 2006 |
Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation.
Topics: Abdominal Fat; Biomarkers; Biopsy; Body Mass Index; Cytokines; Gene Expression; Glucose Intolerance; | 2007 |